Related Experiment Video
Updated: Aug 11, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
The p53 gene family
1Howard Hughes Medical Institute and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, MA 02115, USA. william_kaelin@dfci.harvard.edu
Abstract:
p73 and p63 are two recently discovered p53 homologs. Like p53, these proteins can recognize canonical p53 DNA-binding sites and, when overproduced, can activate p53-responsive target genes and induce apoptosis. Unlike p53, these genes undergo complex alternative splicing which, at least in the case of p63, yields proteins with widely divergent biological properties. In addition p73 and p63 are, in contrast to p53, rarely mutated in human cancer. Furthermore, p73 inactivation is not required for viral transformation. Thus, there is currently no firm evidence that p63 and p73 should be considered tumor suppressors. The early suggestion that monoallelic expression of p73 contributed to carcinogenesis needs to be interpreted cautiously in light of data showing interindividual and intraindividual variation with respect to monoallelic expression of p73 and the finding that p73 mRNA levels are generally increased, rather than decreased, in a host of tumors relative to normal cells.
Insights
p73 and p63 proteins are p53 homologs that rarely mutate in cancer. Evidence does not firmly support p73 and p63 as tumor suppressors, despite earlier hypotheses.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- p73 and p63 are homologous to p53, capable of binding p53 DNA sites and inducing apoptosis.
- Unlike p53, p73 and p63 genes exhibit complex alternative splicing, producing diverse protein isoforms.
- p73 and p63 are infrequently mutated in human cancers, unlike p53.
Purpose of the Study:
- To evaluate the role of p73 and p63 in cancer, specifically addressing their tumor suppressor potential.
- To critically assess the hypothesis that p73 monoallelic expression contributes to carcinogenesis.
Main Methods:
- Comparative analysis of p53, p73, and p63 protein functions.
- Review of mutation data in human cancers for p53, p73, and p63.
- Examination of p73 expression levels and allelic variation in tumor samples.
Main Results:
- p73 and p63 can activate p53-responsive genes and induce apoptosis when overproduced.
- p63 alternative splicing generates proteins with distinct biological activities.
- p73 and p63 are rarely mutated in cancer, and p73 inactivation is not essential for viral transformation.
- p73 mRNA levels are often elevated in tumors, not decreased.
- Inter- and intra-individual variations exist in p73 monoallelic expression.
Conclusions:
- Current evidence does not establish p73 and p63 as tumor suppressors.
- The proposed link between p73 monoallelic expression and carcinogenesis requires cautious interpretation due to expression variability and increased mRNA levels in tumors.
Related Concept Videos
Negative Regulator Molecules
Gene Families
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
DNA Damage can Stall the Cell Cycle
Abnormal Proliferation
DNA Damage Can Stall the Cell Cycle

